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Abstract
Background: Babesia canis is an apicomplexan tick-transmitted hemoprotozoan responsible for causing canine
babesiosis in Europe and west Asia. Despite its importance, there is no known rapid diagnostic kit detection of B.
canis infection in dogs. The present study identified two novel antigens of B. canis and used the recombinant
antigens to establish a rapid, specific and sensitive serodiagnostic technique for detection of B. canis infection.
Methods: A complementary DNA (cDNA) expression library was constructed from the mRNA of B. canis and
immunoscreened using B. canis-infected dog sera. The cDNAs encoding a merozoite surface antigen and a secreted
antigen protein were identified and designated as BcMSA1 and BcSA1, respectively. The recombinant BcMSA1 and
BcSA1 (rBcMSA1 and rBcSA1) expressed in Escherichia coli were purified and injected into mice for production of
anti-sera. The native proteins were characterized by Western blot analysis and immunofluorescence. Furthermore,
indirect enzyme-linked immunosorbent assays (iELISA) and rapid immunochromatographic tests (ICT) based on
rBcMSA1 or rBcSA1 were established and evaluated to test specific antibodies in consecutive plasma samples from
two B. canis-infected dogs.
Results: Antiserum raised against rBcMSA1 and rBcSA1 recognized the 39 kDa and 44 kDa native proteins by
Western blot analysis, respectively. In addition, immunofluorescence and confocal microscopic observations
revealed that BcMSA1 was found on the surface of parasites. However, BcSA1 localized in the matrix of the
merozoites. The ELISA and ICT based on rBcMSA1 or rBcSA1 could detect specific antibodies in consecutive plasma
samples from two B. canis-infected dogs. They showed no cross-reactions against the serum samples collected from
dogs experimentally infected with closely related parasites.
Conclusion: Taken together, the current results indicated that the rBcMSA1 and rBcSA1 are promising
serodiagnostic antigens for developing iELISA and ICT to detect B. canis infection. To our knowledge, this study is
the first to report BcMSA1 and BcSA1 as potential antigenic proteins for serodiagnosis of B. canis infection in dogs.
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Background
Babesia canis is an apicomplexan tick-transmitted proto-
zoan responsible for causing piroplasmosis in dogs [1]. In
many regions of Europe and west Asia, this parasite has been
reported as the important and frequent causative agent of
canine babesiosis [2, 3]. A number of new endemic areas of
B. canis infection had been reported in European countries,
recently [4]. Babesia canis is transmitted by Dermacentor
reticulatus ticks. The symptoms of B. canis infection include:
anorexia, lethargy, jaundice, fever, anemia and lymphadenop-
athy [5]. Currently, control of canine babesiosis relies on
drug therapy and limited vector control measures. However,
drug therapy often relieves symptoms of the infection
without clearing the parasites from the dog’s system.
Therefore, prompt diagnosis of B. canis-infected dogs is
important to prevent the disease.
Microscopic examination of Giemsa-stained blood smears
is still the reasonably sensitive tool for the diagnosis of
canine babesiosis during acute infection. This depends on
detection of intraerythrocytic Babesia organisms, but it is
difficult to detect the parasites during the chronic stage.
Serodiagnostic methods are useful for detecting subclinical
infection with significantly low level of parasitemia. In gen-
eral, indirect immunofluorescence assay (IFAT) and indirect
enzyme-linked immunosorbent assay (iELISA) are com-
monly used diagnostic methods to detect chronic B. canis
infections [6–8]. The above tests are highly sensitive al-
though use of whole parasite antigen derived from infected
erythrocytes possibly yields false-positive results with closely
related parasites due to cross reaction [9]. By comparison,
iELISA and immunochromatographic test (ICT) using
recombinant antigens have advantages because they are
relatively stable and have higher specificity than parasite-
infected erythrocyte antigen-based tests. Although several
iELISA and ICT using purified recombinant antigens have
been established for a range of protozoan diseases [10, 11],
no recombinant antigen-based iELISA and ICT are
available for the serodiagnosis of B. canis-infected
dogs. Therefore, identification and characterization of
novel B. canis antigens are urgently needed for devel-
oping high quality recombinant antigen-based diag-
nostic tests for detection of B. canis infection.
Based on the above background, we constructed a
complementary DNA (cDNA) library of B. canis and
serologically screened the cDNA expression library. A
merozoite surface antigen (BcMSA1) and a secreted
antigen of B. canis (BcSA1) were identified and charac-
terized and their potential as candidates for serodiagno-
sis was evaluated by both iELISA and ICT.
Methods
Parasites and experimental animals
A field strain of B. canis was isolated from a clinical case
located at the Germany-Austria border and stored under
liquid nitrogen. The species was verified by PCR assay
for specific discrimination of B. canis, Babesia rossi and
Babesia vogeli as described previously [12]. Two one-
year-old splenectomized beagle dogs (Nihon Nosan,
Japan) were intravenously injected with 1 × 107 B. canis-
infected erythrocytes. Upon attaining 5–8 % parasitemia,
blood was collected from the two dogs into tubes con-
taining potassium ethylenediaminetetraacetic acid
(EDTA) anticoagulant, and stored at -80 °C for total
RNA extraction. Another two nonsplenectomized beagle
dogs were intravenously infected with 1 × 107 B. canis-
infected erythrocytes. The parasitemia of each dog was
examined every day and the blood was collected for pre-
paring the consecutive plasma samples. Giemsa-stained
thin blood films were prepared daily to monitor the
parasitemia in infected dogs. The blood samples from
two nonsplenectomized dogs were serially collected until
80 or 222 days post-infection (dpi) by using vacuum
tubes with EDTA anticoagulant. The plasma was sepa-
rated from RBC by centrifugation at 1,000 g for 10 min,
both portions were harvested and stored at approxi-
mately -70 °C until use.
Ethical approval
Handing of experimental animals was carried out in
accordance with the guide for the care and use of la-
boratory animals of the National Institutes of Health.
The research protocol was approved (Permit Number:
201109–5) by the Animal Care and Use in Research
Committee Promulgated by Obihiro University of
Agriculture and Veterinary Medicine, Japan. During this
study, all animal surgeries were performed under sodium
pentobarbital anesthesia and all efforts were made to
minimize suffering.
Construction of cDNA expression library
Total RNA was extracted from 36 ml B. canis-infected
dog erythrocytes by acid guanidinium thiocyanate phe-
nol chloroform extraction methods as described previ-
ously [13]. The polyadenylated mRNA was isolated by
Oligotex-dT 30 (JSR and Nippon Roche, Japan) from
1.15 mg of total RNA. The mRNA was precipitated with
3 M sodium acetate and 99.5 % ethanol, after that the
mRNA was washed with 70 % ethanol. Next, using 10
ug mRNA, double stranded complementary DNA was
synthesized by primers containing Xho I and oligo (dT)
sequence from ZAP-cDNA kit, and ligated with Uni-
ZAP XR vector. Subsequently the ligation products were
packaged by using ZAP-cDNA express GigapackIII Gold
cloning kit (Stratagene, USA) in vitro. The cDNA library
titer was determined by incubating 10 μl serial dilutions
of the recombinant bacteriophage with 200 μl of the
XL1-Blue cells (OD600 = 0.5) at 37 °C. The titer of cDNA
expression library constructed was calculated as follows:
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pfu/ml = (number of plaques × dilution factor × 103 μl/
ml)/(μl of diluted phage plated).
Serological analysis of cDNA expression library
The B. canis-infected dog sera were used to immune-
screen the cDNA expression library. The cDNA library
was plated at a density of 1.5 × 104 plaque-forming units
(PFUs) per 100 cm2 square plate on a total of 20 plates.
The phage plaques were overlaid with nitrocellulose mem-
branes and incubated with the B. canis-infected dog
serum following instruction of the PicoBlue Immunoscre-
ening Kit (Stratagene, USA). Briefly, the nitrocellulose
membranes were blocked with 1 % bovine serum albu-
mins (BSA) diluted in Tris-buffered saline (TBS) and then
incubated in a 1:100 dilution of anti-B. canis antibodies
for 2 h. After washing 5 times with TBS containing 0.05 %
Tween20 (TBST) for 5 min, the membranes were treated
with 1:2000 diluted alkaline phosphatase conjugate goat
anti-dog IgG (Bethyl Laboratories Inc., Montgomery, TX,
USA) for 1 h. Then the membranes were washed 4 times
with TBST and once with TBS. For color development, the
membranes were soaked in the fresh substrate (0.3 %
nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-
indolyl phosphate (BCIP) (Roche, Switzerland) and kept in
the dark for 2 min. The membranes were then rinsed with
TBS, dried at room temperature and the positive plaques
were identified on the plate. In order to isolate the single
plaque, all the positive plaques were rescreened three
times, and the positive plaques were selected. Finally, the
cDNA inserts in the lamda vectors were converted into
phagemid vectors after in vivo excision.
DNA sequencing of BcMSA1 and BcSA1 cDNA
The plasmid inserts were rescued in pBluescript SK (pBSK)
by in vivo excision technique using ExAssist Interference-
Resistant Helper Phage with the E. coli SOLR strain follow-
ing the manufacturer’s instructions (Stratagene, USA). The
recombinant plasmids were sequenced using M13 forward,
reverse and internal primers, respectively. The sequence
was analyzed and assembled by using Genetyx software ver-
sion 7.0. The sequence data of the BcMSA1 and BcSA1
was submitted to the GenBank with the accession numbers
KR134351 and KR134352, respectively. The amino acid
sequences of BcMSA1 and BcSA1 were analyzed by a gly-
cosylphosphatidylinositol (GPI) anchor predictor (FragAn-
chor, http://navet.ics.hawaii.edu/∼fraganchor/NNHMM/
NNHMM.html). The secondary structure of BcMSA1
amino acid sequence was predicted by the SOSUI system
(http://harrier.nagahama-i-bio.ac.jp/sosui/).
Southern blot analysis
Genomic DNA of B. canis was extracted from parasite-
infected erythrocytes for Southern blotting. Five micro-
grams of DNA was used for each restriction digestion
analysis using enzymes that did not cut the probe-
specific sequence of BcMSA1 (BamHI, SalI) and BcSA1
(BamHI, SacI). Furthermore, the DNA was also digested
with the restriction enzymes that cut a single site within
the probe-specific sequence of BcMSA1 (PacI, KpnI and
NaeI) and BcSA1 (NheI and KpnI), respectively. The
digested DNA samples were submitted to 1 % (w/v) agar-
ose gel electrophoresis. Then, the fractionated DNA was
transferred to Hybond-N+ nylon membrane (Amersham-
Buchler, Germany). The BcMSA1 and BcSA1 probes that
were PCR-amplified using specific primers were directly
labeled with alkaline phosphatase (GE Healthcare Bio-
Science Co.) and hybridized following the manufacturer’s
instructions. The filters were pre-hybridized at 56 °C for
6 h, and hybridization was carried out at 56 °C for 12 h in
a hybridization oven with labeled probes of full-length of
BcMSA1 and BcSA1, respectively. The blots were washed
for several times. Chemiluminescence signals were gener-
ated using the CDP-Star detection reagent (GE Healthcare
Bio-Science Co.).
Cloning, expression and purification of rBcMSA1 and
rBcSA1 in E. coli
The cDNA fragment of BcMSA1 lacking signal peptide
and truncated gene of BcSA1 was amplified, respectively,
using two pairs of primers: 5′-CGGGATCCGAAAACA




BcSA1 gene. After restriction enzyme digestion, the PCR
products were ligated into the pGEX-4 T vector that was
digested by the same restriction enzymes. After ligation, the
plasmid was transformed into E. coli. The transformed col-
onies were cultured in LB broth medium with ampicillin
sodium (100 μg/ml) at 37 °C, when the OD600 value
reached 0.5, isopropylthio-beta-D-galactosid (IPTG) was
added into logarithmically growing bacterial culture to in-
duce expression of the recombinant BcMSA1 and BcSA1
for 6 h. After centrifugation, the bacteria were harvested
and re-suspended in the lysis buffer (100 mM sodium
phosphate, pH 8.0; 10 mM Tris-Cl, pH 8.0), and then son-
icated for 10 min. Glutathione S-transferase (GST)-tagged
recombinant proteins were incubated with glutathione-
Sepharose 4B beads (Amersham Pharmacia Biotech, USA)
at 4 °C for overnight. The recombinant proteins were re-
covered and the GST tag was cleaved and removed by
thrombin protease. Finally, the concentrations of purified
protein samples were detected by the modified Lowry pro-
tein assay kit (Thermo Scientific, USA).
Production of anti-BcMSA1 and anti-BcSA1 sera
Five 6- to 7-week-old female ICR mice (Clea, Tokyo,
Japan) were immunized intraperitoneally (i.p.) with 100 μg
Zhou et al. Parasites & Vectors  (2016) 9:257 Page 3 of 11
of purified rBcMSA1-GST or rBcSA1-GST in an equal
volume of Freund’s complete adjuvant (Difco Laborator-
ies, USA) for the primary immunization, respectively. Two
booster immunizations were given at 14 day intervals by
i.p. using 100 μg of the same protein emulsified in
Freund’s incomplete adjuvant. Ten days after the last
booster shot, the whole blood was collected and serum
was harvested and stored at -30 °C.
Sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) and Western blot analysis
The recombinant BcMSA1 and BcSA1 proteins were
verified by 10 % SDS-PAGE. Furthermore, mouse anti-
rBcMSA1 and anti-rBcSA1 sera were used to detect the
native BcMSA1 and BcSA1 from B. canis-infected eryth-
rocytes and plasma by Western blot analysis. The B.
canis-infected erythrocytes and plasma (10-time concen-
trated) obtained from infected splenectomized dogs with
8 % parasitemia were sonicated in a loading buffer and
were heated at 100 °C for 10 min. Then the proteins
were size-separated by electrophoresis in 10 % SDS-
PAGE. Afterwards, the proteins were transferred onto a
nitrocellulose membrane for 1 h at 60 mA and blocked
in 5 % PBS skim-milk for 2 h at room temperature. The
blots were incubated with anti-BcMSA1 and anti-BcSA1
polyclonal antibody (1:100) for 1 h. After washing 5
times, the membranes were incubated with horseradish
peroxidase conjugated anti-mouse IgG (1:2,500) for 1 h
at room temperature. The peroxide activity was visual-
ized with 0.05 % (w/v) 3,3′-diaminobenzidine tetrahy-
drochloride in 50 Mm Tris–HCl buffer (pH 7.2)
containing hydrogen peroxide for 2 min. To determine
the antibody responses against BcMSA1 and BcSA1 in
B. canis-infected dogs, the rBcMSA1 and rBcSA1 pro-
teins were subjected to SDS-PAGE analysis. After elec-
trophoresis, the proteins were transferred onto the
membrane and probed with 100 times diluted B. canis-
infected dog sera and pre-infected dog sera, respectively.
The blots were used for western blotting as described
above.
Immunofluorescent antibody test (IFAT) and confocal
laser microscopy observations
Thin blood smears were prepared from B. canis-infected
red blood cells. The smears were air-dried, and fixed in
30 % acetone-70 % methanol solution for 30 min at -30 °
C. The fixed smears were incubated with anti-rBcMSA1
and anti-rBcSA1 sera raised in mice (1:200 dilutions) in
5 % skim milk-PBS for 1 h at 37 °C, respectively. After
washing three times with 1 % PBS-Tween 20 (PBST),
the smears were incubated with Alexa-Fluor 488-
conjugated goat anti-mouse immunoglobulin G (IgG)
(Molecular Probes, USA) for another 1 h at 37 °C.
The slides were washed three times with PBST,
rinsed with PBS and the parasite nucleus was stained
with a solution containing propidium iodide (PI)
(6.25 mg/ml, Wako, Japan) and RNase A (50 mg/ml,
Qiagen, Germany) for 20 min at 37 °C. Finally, the slides
were mounted in a Dako cytomation fluorescent mount-
ing medium (Dako, Carpenteria, CA., USA) and examined
under a confocal laser scanning microscope (TCSNT,
Leica, Germany).
Indirect enzyme-linked immunosorbent assay (iELISA)
based on rBcMSA1 and rBcSA1
Purified GST-rBcMSA1, GST-rBcSA1 and GST (control)
were diluted in a coating buffer (0.05 M carbonate-
bicarbonate buffer, pH 9.6) to a final concentration of
2 μg/ml. The microtiter plates (Thermo Scientific) were
coated with each protein overnight at 4 °C and blocked
with 3 % (w/v) skim milk solution for 1 h at 37 °C. After
washing, the plates were incubated with 200 times di-
luted serum samples from dogs experimentally infected
with Neospora caninum, B. gibsoni, B. rossi, B. vogeli, B.
canis, 30 canine serum samples from non-endemic area
and sequential serum samples from the infected dogs,
respectively. The plates were washed 3 times with PBST
and incubated with horseradish peroxidase (HRP) conju-
gated anti-dog IgG (1:4000) for 1 h at 37 °C. After wash-
ing, the enzyme reaction was developed with 2, 2-azinobis
(3-ethylbenzthiazolinesulfonic acid) (ABTS) (Sigma, USA).
The optical density (OD) was measured at wavelength
of 415 nm and the cut-off values were defined as the
mean value plus 5 × standard deviations of the mean
OD value.
Immunochromatographic test (ICT) based on rBcMSA1
and rBcSA1
The test lines for ICT were prepared by diluting the
GST free rBcMSA1 and rBcSA1 separately in PBS to op-
timal concentration of 200 μg/ml. However, the control
line was prepared from purified mice anti-rBcMSA1 or
anti-rBcSA1 polyclonal IgG, dissolved in PBS to a con-
centration of 1,500 μg/ml. Aliquots of the recombinant
protein solutions were applied to a nitrocellulose mem-
brane using a BioDot Biojet 3050 quanti-dispenser (Bio-
Dot, USA). Colloidal gold-conjugated recombinant
proteins containing 7.5 % BSA were applied to a fiber-
glass membrane and then the membranes were dried at
room temperature. The complete test structures were
assembled and the multimembrane composite was cut
into 2 mm wide strips using a BioDot cutter (BioDot,
USA). Detection was performed by pipetting 50 μl of
the diluted serum (1:10 in PBS) on the sample pad.
The result was judged 30 min after the application of
serum samples.
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Serum samples
Canine sera used for ELISA and ICT were as follows: 12
sera from dogs experimentally infected with B. canis, 3
sera from dogs experimentally infected with B. vogeli, 3
sera from dogs experimentally infected with B. rossi, 3
sera from dogs experimentally infected with B. gibsoni, 3
sera from dogs experimentally infected with Neospora
caninum, 30 sera from specific-pathogen-free (SPF) dogs
and 30 non-endemic control canine serum samples were
collected from non-endemic area in Osaka, Japan, serial
serum samples (from 0 to 222 days post-infection) from
two dogs experimentally infected with B. canis.
Results
Isolation and identification of the cDNA encoding
BcMSA1 and BcSA1
Approximately 20,000 plaques from the B. canis cDNA
expression library were screened with the B. canis-infected
dog serum. A total of 41 immunoreactive recombinant
phage plaques were identified after immunoscreening.
These homogeneous plaques expressing the antigens were
selected and excised to the pBluescript SK phagemid. Ten
of 41 immunoreactive recombinant phage plaques shared
the same sequence, which showed no match with other
genes by Blast. The full length of the BcMSA1 cDNA se-
quence has a single open reading frame of 966 nucleotides
encoding a polypeptide of 321 amino acids. The theoret-
ical isoelectric point and molecular mass for the mature
protein are 4.93 and 33.599 kDa, respectively. Genomic
analyses indicated that BcMSA1 gene contains two introns
and three extrons (Fig. 1a). The predicted transmembrane
region of BcMSA1 was determined according to the com-
puted algorithm (Fig. 1b). Kyte-Doolittle’s hydropathy ana-
lysis indicated that the amino acid sequence of BcMSA1
has a hydrophilic core region with a good antigenic index,
which suggested that the antigen could be a good candi-
date for detection of B. canis antibodies (data not shown).
GPI anchor prediction indicated that three of highly prob-
ably GPI sequences were involved in BcMSA1. One GPI
sequence located from 297–321 of this amino acid
sequence, and another two located from 304–321 and
305–321, respectively. Furthermore, another novel gene
named BcSA1 was also identified from these 41 immuno-
reactive recombinant phage plaques. The partial length of
BcSA1 contained 1,255 nucleotides encoding a polypep-
tide with 417 amino acid residues (Fig. 1c). The isoelectric
Fig. 1 The hypothetical transmembrane helix of BcMSA1 in the membrane using the SOSUI bioinformatic tool. a Structure of the genomic
BcMSA1 gene. White bold lines indicate exons, and black rectangles indicate introns. The numeric numbers indicate the number of nucleotides;
b BcMSA1 was predicted to have two hypothetical transmembrane helixes located at the N and C terminal; c Nucleotide sequence and predicted
amino acid sequences of the genomic BcSA1 gene
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point and molecular mass for the mature protein without
signal peptide were 8.77 and 44.06 kDa, respectively. Un-
like BcMSA1, the BcSA1 had not predicted GPI-anchored
domains in its amino acid sequence.
Southern blot analysis
Southern blot analysis was performed to determine the
copy number of BcMSA1 and BcSA1 gene, respectively.
A probe derived from cDNA clone BcMSA1 was
strongly hybridized to the B. canis DNA fragments, as
shown in Fig. 2a. Treatment with the restriction
enzymes (BamHI and SalI) that do not cut within the
sequence consistent with the probe produced a single
band (Fig. 2a, lanes 1, 2). However, two bands were ob-
served after treatment with enzymes (PacI, KpnI and
NaeI) that cut a single position with the probe sequence
(Fig. 2a, lanes 3–5). These results revealed that the gen-
omic DNA of B. canis contains a single-copy gene
encoding BcMSA1. Similar result was also observed for
BcSA1 cDNA with the restriction enzymes that cut once
within the gene (Fig. 2b, lanes 3, 4) and those that did
not cut with the gene (Fig. 2b, lanes 1, 2). These results
also indicate that the BcSA1 gene exists as a single copy
in B. canis genome.
Expression, purification and Western blot analysis of
rBcMSA1 and rBcSA1
The amplified BcMSA1 and BcSA1 genes were cloned
into the prokaryotic expression vector pGEX-4 T-1, re-
spectively. Both BcMSA1 and BcSA1 were expressed in
E. coli as soluble GST-fusion proteins with molecular
mass of approximately 64 kDa (Fig. 3a, lane 1; Fig. 3c,
lane 1). Western blot analysis showed that serum anti-
bodies from dogs experimentally infected with B. canis
could react with both of the recombinant fusion proteins
(Fig. 3a, lane 3; Fig. 3c, lanes 4, 5). In contrast, no reac-
tion of the serum was obtained with the GST protein
(Fig. 3a, lane 4; Fig. 3c, lane 6).
Characterization of the native BcMSA1 and BcSA1 of B.
canis
Mouse anti-rBcMSA1 and anti-rBcSA1 polyclonal sera
were prepared and used to identify native BcMSA1 and
BcSA1 in B. canis parasites by Western blot analysis and
confocal laser scanning microscopy. As shown in Fig. 3b
the 39 kDa band was detected with mouse anti-
rBcMSA1 sera in B. canis-infected erythrocyte lysate
(Fig. 3b, lane 1). There was no reaction for the normal
erythrocyte lysate with the anti-rBcMSA1 serum (Fig. 3b,
lane 2). On the other hand, the predicted 44 kDa band
was detected by mouse anti-rBcSA1 sera in the plasma
from B. canis-infected dog during acute stage of infec-
tion (Fig. 3d, lane 1). Furthermore, the mouse anti-
rBcMSA1 serum did not react with the plasma of B.
canis-infected dog and the mouse anti-rBcSA1 serum
did not react with B. canis-infected erythrocyte lysate in
Western blot analysis (data not shown). Native protein
localization studies by IFAT revealed that BcMSA1 and
BcSA1 possibly localizes on the cell surface (Fig. 4a) and
within the cytoplasm of the parasite (Fig. 4b), respectively.
Evaluation of the serodiagnostic potential of rBcMSA1
and rBcSA1 by iELISA
The rBcMSA1- and rBcSA1-based ELISA experiments
were conducted to investigate whether these recombin-
ant proteins could be used for diagnosis of B. canis
infection in dogs. The cut-off values of BcMSA1-ELISA
and BcSA1-ELISA were calculated using 30 SPF canine
sera; these were 0.149 and 0.110, respectively (Fig. 5c, d).
As shown in Fig. 5c and d, all the serum samples from
dogs infected with B. canis were positive for these two
antigens, whereas, all 30 canine serum samples from
non-endemic area (N) were negative. The serum samples
from B. rossi-infected dogs (Br), B. vogeli-infected dogs
(Bv), B. gibsoni-infected dogs (Bg) and N. caninum-in-
fected dogs (Nc) were negative for the antibodies against
BcMSA1 and BcSA1. The sensitivity of these assays were
tested with sequential sera obtained from two dogs ex-
perimentally infected with B. canis, both serologically
negative prior to infection. For the BcMSA1-ELISA, the
IgG titers increased in one dog on day 9 post-infection
and in another dog on day 11 post-infection. Both dogs
were serologically positive until 80 days post-infection
(Fig. 5a, b). Towards day 80, the dogs already entered
the chronic phase of the disease, evidenced by
Fig. 2 Southern blot analysis of genomic DNA of Babesia canis.
a Genomic DNA was digested with different restriction enzymes,
BamHI (lane 1), SalI (lane 2), PacI (lane 3), and KpnI (lane 4) and NaeI
(lane 5), and hybridized with specific probe of the BcMSA1 gene;
b Genomic DNA was digested with different restriction enzymes,
BamHI (lane 1), SacI (lane 2), NheI (lane 3), and KpnI (lane 4), and
hybridized with a specific probe of the BcSA1 gene
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recovering hematocrit value (data not shown) and sig-
nificantly low levels of parasitemia. In contrast, specific
antibodies against BcSA1 were detected on day 24 post-
infection in one dog and on day 21 post-infection in an-
other dog. Interestingly, the two dogs were serologically
positive for BcSA1 throughout the sampling period.
Evaluation of the serodiagnostic potential of rBcMSA1
and rBcSA1 by ICT
The performance of rBcMSA1 and rBcSA1 as rapid and
simple diagnostic antigens for detection of B. canis in-
fection in dogs was evaluated using ICT. Serum sam-
ples from experimentally infected dogs with closely
related parasites (B. rossi, B. vogeli, B. gibsoni and N.
caninum) were used to determine the specificity of
ICT based on rBcMSA1 and rBcSA1. Only the serum
samples from B. canis-infected dogs were positive in
the ICT, the other serum samples and SPF dog sera
were negative (Fig. 6). As shown in Fig. 6, the specific
antibodies to BcMSA1 and BcSA1 could be detected
from day 9 and day 21, respectively. The antibodies
against BcMSA1 and BcSA1 were detectable until
80 days post-infection, which was consistent with the
results of the iELISA.
Discussion
Canine babesiosis frequently caused by Babesia canis is an
emerging infectious disease in central Europe [14, 15]. A
Fig. 3 SDS-PAGE and immunoblot analysis of recombinant and native BcMSA1 and BcSA1. a The 10 % SDS-PAGE stained with Coomassie blue:
recombinant BcMSA1 fused with GST (lane 1) and GST (lane 2). Western blot analysis of recombinant protein: recombinant BcMSA1 (lane 3) and
GST (lane 4) probed with B. canis-infected dog serum; b Western blot analysis of native BcMSA1. B. canis-infected erythrocyte lysate (lane 1) and
normal canine erythrocyte lysate (lane 2) probed with anti-rBcMSA1 mouse serum; c The 10 % SDS-PAGE stained with Coomassie blue: recombinant
BcSA1 fused with GST (lane 1), recombinant BcSA1 fused without GST (lane 2) and GST (lane 3). Western blot analysis of recombinant protein:
recombinant BcMSA1 (lane 4), recombinant BcSA1 fused without GST (lane 5) and GST (lane 6) probed with B. canis-infected dog serum;
d Western blot analysis of native BcMSA1. The plasma from a dog infected with B. canis (lane 1) and a normal dog (lane 2) probed with
anti-rBcMSA1 mouse serum
Fig. 4 Localization of BcMSA1 and BcSA1 at inner and outer surface of erythrocyte stages of B. canis by immunofluorescence staining and laser
confocal microscopy. a Observation of the native BcMSA1 in thin blood smears of B. canis-infected RBC stained with mice anti-rBcMSA1 serum
and pre-immune serum; b Observation of the native BcSA1 in thin blood smears of B. canis-infected RBC stained with mice anti-rBcSA1 serum
and pre-immune serum: (i) Phase-contrast images; (ii) Propidium iodide staining; (iii) Immunofluorescent staining; (iv) Merged image
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number of new endemic regions of this disease have been
reported in European countries and beyond [16–19].
Canine babesiosis also represents an important veterinary
medical problem, since to date treatment and diagno-
sis of this disease is still limited and the current vac-
cine is derived from culture supernatants [20–22].
Therefore, it is critical to have sensitive and reliable
tests for screening the B. canis positive population for
prompt intervention. In this regard, we attempted to
identify novel antigens to develop reliable, rapid and
sensitive diagnostic methods for B. canis infections. A
cDNA expression library was constructed from B.
canis merozoites mRNA and serologically screened
with B. canis-infected serum, and novel BcMSA1 and
BcSA1 were isolated and identified in this study.
Homology blast result indicated that BcMSA1 shared
no significant homology with any of the apicomplexan
parasites, which was important to confer a degree of
specificity when used as a diagnostic probe. A 39 kDa
native protein of B. canis merozoites was recognized in
Western blot analysis. The molecular mass of this native
protein was higher than predicted. The difference in the
molecular mass could be attributed to glycosylation
modification since two predicted N-glycosylation sites
were identified in BcMSA1 motif by the NetNGlyc pre-
dictor or the PROSITE pattern PS00001 (data not
shown). Furthermore, BcMSA1 was identified as a sur-
face protein of B. canis merozoites. Generally, the mero-
zoite surface proteins of Babesia spp. are thought to be
the main targets for the host immune responses. For the
Babesia spp., merozoite surface proteins are usually in-
volved in the merozoite invasion of host erythrocytes
and provide potential targets for vaccine and serodiagnosis
[23–26]. Therefore, BcMSA1 might be a potential candi-
date for diagnostic antigen and vaccines for diagnosis and
prevention of B. canis infection, respectively. However, the
merozoite surface antigens of Babesia spp. are genetically
diverse among the different isolates [24, 25]. Thus, more
sequences of BcMSA1 from different regions should be
identified for further study.
Sequence analysis of BcSA1 revealed that this antigen
contained a partial of signal peptide sequence, and
BcSA1 shared 25 % amino acid identity with B. gibsoni
secreted antigen 1 (BgSA1) in previous report [27]. Fur-
thermore, a 44 kDa native protein was detected by
Western blot, and this was consistent with the molecular
Fig. 5 Evaluation of rBcMSA1 and rBcSA1 as diagnostic antigens by ELISA system. a, b Antibody responses of sequential serum samples from
two non-splenectomized dogs experimentally infected with B. canis to rBcMSA1 and rBcSA1 antigens in iELISA; c, d The reactivity of rBcMSA1
and rBcSA1 with B. canis and closely related parasite-infected dog sera. Abbreviations: Bc, B. canis-infected dogs sera; SPF, SPF dog sera; Br, B. rossi-
infected dogs sera; Bv, B. vogeli-infected dogs sera; Bg, B. gibsoni-infected dogs sera; Nc, N. caninum-infected dogs sera; N, serum samples from
non-endemic area in Osaka, Japan
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mass of BcSA1 without signal peptide. Therefore, the
results indicated that BcSA1 may represent a secreted
protein of B. canis. Secreted proteins have been proved as
suitable sources of antigens for the detection of parasites
infection in previous studies [27–31]. Therefore, identifi-
cation of BcSA1 will be very useful in the development of
effective diagnostic methods for the detection of circulat-
ing antigens and antibodies during B. canis infection. In
addition, another unexpected 69 kDa band was observed
in the 10-time concentrated B. canis-infected dog plasma
from both infected and non-infected dogs in the Western
blot analysis, which might be dog IgG cross-reacted with
the second antibody to give an unspecific band.
To determine the diagnostic potential of the rBcMSA1
and rBcSA1 in the serological assays, the recombinant
proteins were used as antigens in iELISAs. The results of
specificity analysis indicated that both BcMSA1 and
BcSA1 were specific for B. canis infection. This makes
the two antigens become suitable candidates for diagno-
sis of B. canis infection by iELISA. On the other hand,
BcMSA1-ELISA and BcSA1-ELISA could detect the spe-
cific antibody as early as 9 and 22 days post-infection,
respectively. Moreover, the antigen-antibody interactions
were still detectable until the chronic stage of infection
with both antigens. These results indicated that both
rBcMSA1 and rBcSA1 can detect chronic B. canis infec-
tion in dogs and the BcMSA1 can detect B. canis during
early infection. The ability of BcMSA1 and BcSA1 to
induce strong humoral immunity in B. canis-infected
dogs necessitates further evaluation of the recombinant
antigens as vaccine candidates against B. canis infection.
Immunochromatographic test (ICT) is a one-step
rapid diagnostic method, which is suitable for various
clinical environment and can be completed in a short
time (10–15 min) [32, 33]. Therefore, in this study, we
established ICT methods for detection of B. canis
infection. The ICT based on rBcMSA1 or rBcSA1 could
detect the specific antibodies from dogs with B. canis in-
fection. These results suggest that rBcMSA1 and rBcSA1
could be candidate antigens for the development of ICT
to detect B. canis infection.
Conclusion
In this study, a B. canis cDNA expression library was con-
structed and immunoscreened using B. canis-infected dog
sera. This study was the first to identify and characterize
two novel antigens of B. canis encoding a merozoite
surface antigen (BcMSA1) and a secreted protein (BcSA1)
as potential serodiagnostic antigens. Our results demon-
strated that both, rBcMSA1 and rBcSA1, were highly
Fig. 6 Evaluation of ICT based on rBcMSA1 and rBcSA1. a Cross-reactivity of ICT using rBcMSA1 with closely related parasite-infected canine sera:
lane 1, B. rossi-infected dog serum; lane 2, B. vogeli-infected dog serum; lane 3, B. gibsoni-infected dog serum; lane 4, L. infantum-infected dog
serum; lane 5, B. canis-infected dog serum; lane 6, a SPF dog serum; b Specific antibody responses to rBcMSA1 in sequential serum samples from
a non-splenectomized dog experimentally infected with B. canis; c Cross-reactivity of rBcSA1 with closely related parasite-infected canine sera:
lane 1, SPF dog serum; lane 2, B. canis-infected dog serum; lane 3, B. rossi-infected dog serum; lane 4, B. vogeli-infected dog serum; lane 5,
B. gibsoni-infected dog serum; lane 6, L. infantum-infected dog serum; d Specific antibody responses to rBcSA1 in sequential serum samples
from a non-splenectomized dog experimentally infected with B. canis
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sensitive and specific for serodiagnosis of B. canis infec-
tion. Taken together, rBcMSA1 and rBcSA1 could be the
first promising serodiagnostic antigens based on iELISA
and ICT for detecting B. canis infection in dogs.
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